United States· US:70370-5250_f5cc43fd-6e18-4a06-8c9f-bd80ea847e83

Crenessity

A medicinal product containing crinecerfont, registered in United States by Neurocrine Biosciences, Inc..

US label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedCrenessityATC—REGISTER NO.US:70370-5250_f5cc43f…PACKS LISTED2CHECKEDJuly 26, 2026

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
CRINECERFONT
Manufacturer
Neurocrine Biosciences, Inc.
Country
United States (US)
ATC code
—
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
July 26, 2026

Packs & prices · 2

  • ndc11
    7037052501
    30 mL in 1 BOTTLE (70370-5250-1)
  • ndc11
    70370-5250-1

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ec7eeec8-8c12-411a-b00f-58f3f62f9928
GET /v1/drugs/ec7eeec8-8c12-411a-b00f-58f3f62f9928?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "ORAL",
  "source": "ndc",
  "strength": "50",
  "substance": "CRINECERFONT",
  "productndc": "70370-5250",
  "dosage_form": "SOLUTION",
  "dea_schedule": null,
  "strength_unit": "mg/mL",
  "application_number": "NDA218820",
  "marketing_category": "NDA"
}

See everything about crinecerfont.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.